| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
169,410,000 |
| Market
Cap: |
97.83(M) |
| Last
Volume: |
3,856,623 |
Avg
Vol: |
3,846,057 |
| 52
Week Range: |
$0.35 - $0.885 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Health Services |
| Level
III Sector: |
Medical Instruments & Supplies |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Inovio Pharmaceuticals is a biotechnology company focused on bringing the designed deoxyribonucleic acid (DNA) medicines and vaccines to help protect people from infectious diseases, including COVID-19, and to help treat people with cancer, and conditions associated with human papillomavirus. Co.'s DNA medicines pipeline is comprised of three types of product candidates: prophylactic DNA vaccines, therapeutic DNA immunotherapies, and DNA encoded monoclonal and bispecific antibodies, all of which utilize the two components of Co.'s integrated platform, SynCon® and CELLECTRA®. Co. is evaluating the feasibility of, conducting or planning clinical studies of its DNA medicines.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
5,700 |
37,076 |
| Total Sell Value |
$0 |
$0 |
$3,192 |
$60,923 |
| Total People Sold |
0 |
0 |
1 |
3 |
| Total Sell Transactions |
0 |
0 |
1 |
5 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bagarazzi Mark |
Chief Medical Officer |
• – – |
2017-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,333 |
28,825 |
|
- |
|
| Sardesai Niranjan |
Chief Operating Officer |
• – – |
2017-01-04 |
4 |
OE |
$6.12 |
$60,056 |
D/D |
9,813 |
58,247 |
|
- |
|
| Sardesai Niranjan |
Chief Operating Officer |
• – – |
2016-08-29 |
4 |
S |
$9.30 |
$202,733 |
D/D |
(21,800) |
48,434 |
|
- |
|
| Sardesai Niranjan |
Chief Operating Officer |
• – – |
2016-08-28 |
4 |
OE |
$6.12 |
$202,670 |
D/D |
33,116 |
70,234 |
|
- |
|
| Collins Morton |
Director |
– • – |
2016-06-28 |
4 |
B |
$9.13 |
$91,309 |
D/D |
10,000 |
142,291 |
2.39 |
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2016-06-08 |
4 |
D |
$11.24 |
$1,246,134 |
D/D |
(110,866) |
1,955,642 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2016-06-08 |
4 |
OE |
$5.08 |
$1,246,124 |
D/D |
245,300 |
2,066,508 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2016-05-18 |
4 |
S |
$10.37 |
$64,819 |
D/D |
(6,250) |
17,798 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2016-05-18 |
4 |
OE |
$8.92 |
$55,750 |
D/D |
6,250 |
24,048 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2016-05-09 |
4 |
D |
$9.52 |
$86,613 |
D/D |
(9,098) |
1,821,208 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2016-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
23,334 |
1,830,306 |
|
- |
|
| Wysenski Nancy |
Director |
– • – |
2016-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Mahmoud Adel |
Director |
– • – |
2016-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Benito Simon X |
Director |
– • – |
2016-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
17,798 |
|
- |
|
| Cabrera Angel |
Director |
– • – |
2016-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
41,750 |
|
- |
|
| Collins Morton |
Director |
– • – |
2016-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
132,291 |
|
- |
|
| Dhillon Avtar S |
Director |
– • – |
2016-05-08 |
4 |
OE |
$0.00 |
$0 |
D/D |
5,000 |
63,333 |
|
- |
|
| Collins Morton |
Director |
– • – |
2016-04-15 |
4 |
B |
$9.45 |
$650,925 |
I/I |
68,400 |
64,750 |
2.1 |
- |
|
| Weiner David B. |
Director |
– • – |
2016-03-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
723,622 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2016-03-07 |
4 |
D |
$7.48 |
$33,211 |
D/D |
(4,440) |
1,806,972 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2016-03-07 |
4 |
D |
$7.48 |
$23,906 |
D/D |
(3,196) |
26,526 |
|
- |
|
| Bagarazzi Mark |
Chief Medical Officer |
• – – |
2016-03-07 |
4 |
D |
$7.48 |
$21,258 |
D/D |
(2,842) |
20,492 |
|
- |
|
| Sardesai Niranjan |
Chief Operating Officer |
• – – |
2016-03-07 |
4 |
D |
$7.48 |
$24,056 |
D/D |
(3,216) |
37,118 |
|
- |
|
| Kim Jong Joseph |
Chief Executive Officer |
• • – |
2016-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,334 |
1,811,412 |
|
- |
|
| Kies Peter |
CFO |
• – – |
2016-03-05 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,334 |
29,722 |
|
- |
|
363 Records found
|
|
Page 14 of 15 |
|
|
